Photo Rounds

Fade haircut or something else?

An 18-year-old female-to-male (FTM) transgender man with past medical history significant for depression (managed with lithium, naltrexone, and bupropion) and gastroesophageal reflux disease (GERD) presented for routine follow-up. The physician noted that the patient had hair loss and areas of different hair lengths over his temples. The patient denied any pruritus or rashes.

What’s your diagnosis?


 

References

Different hair lengths

The areas of hair loss and different length hairs in a patient with otherwise normal-density hair was consistent with a diagnosis of trichotillomania. The physician initially thought the patient had a “fade” hairstyle, but then observed him twirling his hair. Further queries confirmed a history of hair pulling (trichotillomania) and ingesting the hair (trichophagia).

In adulthood, trichotillomania affects females about 4 times more than males, although in childhood, the sex distribution appears about equal.1 The typical age of onset is between 10 to 13 years. Several mental health conditions are associated with trichotillomania, such as major depressive disorder, anxiety disorders, and substance use disorder, with trichotillomania generally preceding these comorbid disorders. It is important to rule out obsessive compulsive disorder and consider body dysmorphic disorder when making a diagnosis of trichotillomania.1

It is common to see androgenetic alopecia precipitated by hormone therapy in FTM individuals. This would usually cause thinning of the hair rather than the irregular hair lengths and pattern seen in this patient. Tinea capitis is also part of the differential diagnosis in a case such as this. It can be diagnosed by potassium hydroxide (KOH) preparations in the setting of friable and broken hair shafts (and sometimes erythema and inflammation).

Patients with trichotillomania may have hair with blunt or tapered ends; hair may also look like uneven stubble.2 The scalp is the most commonly involved site (72.8%), followed by eyebrows (50.7%), and the pubic region (50.7%).1 Useful diagnostic clues include an unusual shape of the affected area, accessible location, and a changing pattern from visit to visit.2 If trichotillomania is suspected, it might be useful to ask about hair-playing activities, such as twirling or twisting, or playing with the ends of eyelashes or eyebrows.2

Unwanted medical consequences of trichotillomania include skin damage (if sharp instruments are used for hair pulling), and the formation of gastrointestinal trichobezoars (hairballs) if trichophagia is present. Trichobezoars that cause bowel obstructions may need surgical intervention.1

Behavioral therapy is the first-line treatment for trichotillomania in all age groups.1,3 Treating any coexisting mental health disorders is also essential. There are currently no FDA-approved medications for treatment; however, there is evidence that N-acetylcysteine may be useful in treating adults with trichotillomania and other repetitive skin disorders.3 Antipsychotics and cannabinoid agonists also may be beneficial.1

This patient was continued on his current lithium, naltrexone, and bupropion regimen (rather than adding additional psychiatric medicines) as he was doing better than his previous baseline. He was advised to continue with his cognitive behavioral therapy. His hormone replacement therapy also was continued because it was not thought to be contributory. He was provided with education about symptoms of trichobezoar and red flag symptoms (eg, worsening nausea, vomiting, abdominal pain) that would necessitate emergency follow-up. His GERD symptoms were thought not to be related to his trichophagia. He was scheduled to follow up for routine primary care in 6 months.

Photo courtesy of Daniel Stulberg, MD. Text courtesy of Sarasawati Keeni, MD, and Daniel Stulberg, MD, FAAFP, Department of Family and Community Medicine, Western Michigan University Homer Stryker, MD School of Medicine, Kalamazoo.

Recommended Reading

Experts share their sun protection tips for children
MDedge Family Medicine
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
MDedge Family Medicine
FDA warns of tattoo ink tied to dangerous infections
MDedge Family Medicine
A 63-year-old male presented for evaluation of worsening genital lesions and associated swelling
MDedge Family Medicine
Prognostic factors of SCCs in organ transplant recipients worse compared with general population
MDedge Family Medicine
Warts difficult to eradicate in immunocompromised children
MDedge Family Medicine
FDA passes on olorofim despite critical need for antifungals
MDedge Family Medicine
Study supports new NCCN classification for cutaneous squamous cell carcinoma
MDedge Family Medicine
FDA approves ritlecitinib for ages 12 and up for alopecia areata
MDedge Family Medicine
Imaging techniques will revolutionize cancer detection, expert predicts
MDedge Family Medicine